Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 16 results.
User Information
Export Records
  1. 1.   Immunotoxin SS1P is rapidly removed by proximal tubule cells of kidney, whose damage contributes to albumin loss in urine
  2. Liu, Xui-Fen; Wei, Junxia; Zhou, Qi; Molitoris, Bruce A; Sandoval, Ruben; Kobayashi, Hisataka; Okada, Ryuhei; Nagaya, Tadanobu; Karim,Baktiar; Butcher,Donna; Pastan, Ira
  3. Proceedings of the National Academy of Sciences of the United States of America. 2020, MAR 17; 117(11): 6086-6091.
  1. 2.   Design, expression and characterization of a soluble single-chain functional human neonatal Fc receptor
  2. Feng, Y.; Gong, R.; Dimitrov, D. S.
  3. Protein Expression and Purification. 2011, Sep; 79(1): 66-71.
  1. 3.   Bifunctional fusion proteins of the human engineered antibody domain m36 with human soluble CD4 are potent inhibitors of diverse HIV-1 isolates
  2. Chen, W. Z.; Xiao, X. D.; Wang, Y. P.; Zhu, Z. Y.; Dimitrov, D. S.
  3. Antiviral Research. 2010, Oct; 88(1): 107-115.
  1. 4.   Regulation of ITAM-positive receptors: role of IL-12 and IL-18
  2. Ortaldo, J. R.; Winkler-Pickett, R.; Wigginton, J.; Horner, M.; Bere, E. W.; Mason, A. T.; Bhat, N.; Cherry, J.; Sanford, M.; Hodge, D. L.; Young, H. A.
  3. Blood. 2006, FEB 15; 107(4): 1468-1475.
  1. 5.   A glutathione S-transferase pi-activated prodrug causes kinase activation concurrent with S-glutathionylation of proteins
  2. Townsend, D. M.; Findlay, V. J.; Fazilev, F.; Ogle, M.; Fraser, J.; Saavedra, J. E.; Ji, X. H.; Keefer, L. K.; Tew, K. D.
  3. Molecular Pharmacology. 2006, FEB; 69(2): 501-508.
  1. 6.   Injectable formulation of disodium 1-[2-(carboxylato)pyrrolidin-1-yl]diazen-1-ium-1,2-diolate (PROLI/NO), an ultrafast nitric oxide donor prodrug
  2. Waterhouse, D. J.; Saavedra, J. E.; Davies, K. M.; Citro, M. L.; Xu, X.; Powell, D. A.; Grimes, G. J.; Potti, G. K.; Keefer, L. K.
  3. Journal of Pharmaceutical Sciences. 2006, JAN; 95(1): 108-115.
  1. 7.   Analysis of albumin-associated peptides and proteins from ovarian cancer patients
  2. Lowenthal, M. S.; Mehta, A. I.; Frogale, K.; Bandle, R. W.; Araujo, R. P.; Hood, B. L.; Veenstra, T. D.; Conrads, T. P.; Goldsmith, P.; Fishman, D.; Petricoin, E. F.; Liotta, L. A
  3. Clinical Chemistry. 2005, OCT; 51(10): 1933-1945.
  1. 8.   Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma
  2. Ryan, Q. C.; Headlee, D.; Acharya, M.; Sparreboom, A.; Trepel, J. B.; Ye, J.; Figg, W. D.; Hwang, K.; Chung, E. J.; Murgo, A.; Melillo, G.; Elsayed, Y.; Monga, M.; Kalnitskiy, M.; Zwiebel, J.; Sausville, E. A.
  3. Journal of Clinical Oncology. 2005, JUN 10; 23(17): 3912-3922.
  1. 9.   In search of a novel anti-HIV drug: Multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6dimethylphenyl] amino]-2-pyrimidinyl]amino]-benzonitrile (R278474, rilpivirine)
  2. Janssen, P. A. J.; Lewi, P. J.; Arnold, E.; Daeyaert, F.; de Jonge, M.; Heeres, J.; Koymans, L.; Vinkers, M.; Guillemont, J.; Pasquier, E.; Kukla, M.; Ludovici, D.; Andries, K.; de Bethune, M. P.; Pauwels, R.; Das, K.; Clark, A. D.; Frenkel, Y. V.; Hughes, S. H.; Medaer, B.; De Knaep, F.; Bohets, H.; De Clerck, F.; Lampo, A.; Williams, P.; Stoffels, P.
  3. Journal of Medicinal Chemistry. 2005, MAR 24; 48(6): 1901-1909.
  1. 10.   Kinetic stability and crystal structure of the viral capsid protein SHP
  2. Forrer, P.; Chang, C. S.; Ott, D.; Wlodawer, A.; Pluckthun, A.
  3. Journal of Molecular Biology. 2004, NOV 12; 344(1): 179-193.
  1. 11.   Ceramidase expression facilitates membrane turnover a and endocytosis of rhodopsin in photoreceptors
  2. Acharya, U.; Mowen, M. B.; Nagashima, K.; Acharya, J. K.
  3. Proceedings of the National Academy of Sciences of the United States of America. 2004 101(7): 1922-1926.
  1. 12.   Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: Mechanism and therapeutic implications
  2. Rapisarda, A.; Uranchimeg, B.; Sordet, O.; Pommier, Y.; Shoemaker, R. H.; Melillo, G.
  3. Cancer Research. 2004 64(4): 1475-1482.
  1. 13.   Ex vivo and in vivo biological effects of a truncated form of the receptor tyrosine kinase Stk when activated by interaction with the friend spleen focus-forming virus envelope glycoprotein or by point mutation
  2. Rulli, K.; Yugawa, T.; Hanson, C.; Thompson, D.; Ruscetti, S.; Nishigaki, K.
  3. Journal of Virology. 2004 78(9): 4573-4581.
  1. 14.   Facile photochemical synthesis of mixed siloxyacetal glycosides as potential pH-sensitized prodrugs for selective treatment of solid tumors
  2. Svarovsky, S. A.; Taraban, M. B.; Barchi, J. J.
  3. Organic & Biomolecular Chemistry. 2004 2(21): 3155-3161.
  1. 15.   Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells
  2. Honjo, Y.; Hrycyna, C. A.; Yan, Q. W.; Medina-Perez, W. Y.; Robey, R. W.; van de Laar, A.; Litman, T.; Dean, M.; Bates, S. E.
  3. Cancer Research. 2001 61(18): 6635-6639.
  1. 16.   Structure-based design of HIV protease inhibitors: pharmacokinetic optimization
  2. Stinson, S. F.; Randad, R. S.; Clanton, D.; House, T.; Lubkowska, L.; Erickson, J. W.
  3. HIV Pathogenesis and Treatment Conference. 1998, 56 (abstract no. 2039).
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel